CollabRx Debuts Cancer Genomics Service to Distinguish Itself from DTC Genomics Firms

The web-based CollabRx One program, which will charge cancer patients between $50,000 and $100,000 to generate genetically-targeted treatment options, compares 15,000 genes against tumor samples to gauge how they respond to as many as 5,000 drugs.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.